EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical Outcomes for Patients With Monomicrobial vs Polymicrobial Acinetobacter baumannii-calcoaceticus Complex Infections Treated With Sulbactam-Durlobactam or Colistin: A Subset Analysis From a Phase 3 Clinical Trial

Sarah M McLeod iD, Alita A Miller iD, Khurram Rana, David Altarac, Samir H Moussa iD, Adam B Shapiro iD

Open Forum Infectious Diseases · 28.03.2024 · 11 (4)

DOI: 10.1093/ofid/ofae140 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Open Forum Infectious Diseases, online erschienen am 20.03.2024. Verfasst von Sarah M McLeod und 5 weiteren Autor:innen. Beteiligte Einrichtung: Entasis Therapeutics, Inc, an affiliate of Innoviva Specialty Therapeutics, Inc, Waltham, Massachusetts, USA. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 13 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Entasis Therapeutics, Inc, Innoviva Specialty Therapeutics, Inc, Zai Labs.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

In a previous study, the efficacy and safety of sulbactam-durlobactam vs colistin for the treatment of patients with carbapenem-resistant Acinetobacter baumannii-calcoaceticus complex (CRABC) infections were evaluated in a randomized controlled phase 3 trial. Both arms were dosed on a background of imipenem-cilastatin to treat coinfecting gram-negative pathogens. Thirty-six percent of infections in the primary efficacy population were polymicrobial.

Methods

A subset analysis was performed to compare clinical and microbiological outcomes at test of cure (7 ± 2 days after the last dose) for patients with monomicrobial and polymicrobial CRABC infections. Minimal inhibitory concentrations of antibiotics against baseline isolates were determined by broth microdilution according to Clinical and Laboratory Standards Institute methodology.

Results

Clinical cure, 28-day all-cause mortality, and microbiological outcomes were similar for patients in the sulbactam-durlobactam treatment arm with monomicrobial or polymicrobial A baumannii-calcoaceticus infections. Patients in the colistin arm with monomicrobial CRABC infections had higher mortality rates with worse clinical and microbiological outcomes as compared with those with polymicrobial infections. For patients who received sulbactam-durlobactam, imipenem susceptibility of coinfecting gram-negative pathogens trended with clinical benefit for patients with polymicrobial A baumannii-calcoaceticus infections. When tested in vitro, durlobactam restored imipenem susceptibility to the majority of coinfecting gram-negative pathogens from the sulbactam-durlobactam arm. This phenotype appeared to be related to the clinical outcome in 13 of 15 evaluable cases.

Conclusions

These results suggest that the use of sulbactam-durlobactam plus a carbapenem could be an effective approach to treat polymicrobial infections that include CRABC, but additional clinical data are needed to demonstrate efficacy.

Schlagwörter

Stichwörter der Autor:innen

Acinetobactercarbapenem-resistantpneumoniapolymicrobial infectionsulbactam-durlobactam

Autor:innen und Institutionen

  • Entasis Therapeutics, Inc, an affiliate of Innoviva Specialty Therapeutics, Inc, Waltham, Massachusetts, USA.

ORCID-Profile: Sarah M McLeod, Alita A Miller, Samir H Moussa, Adam B Shapiro

Förderung

  • Entasis Therapeutics, Inc
  • Innoviva Specialty Therapeutics, Inc
  • Zai Labs

Zitieren

APA

McLeod, S. M., Miller, A. A., Rana, K., Altarac, D., Moussa, S. H., & Shapiro, A. B. (2024). Clinical Outcomes for Patients With Monomicrobial vs Polymicrobial Acinetobacter baumannii-calcoaceticus Complex Infections Treated With Sulbactam-Durlobactam or Colistin: A Subset Analysis From a Phase 3 Clinical Trial. Open Forum Infectious Diseases, 11(4). https://doi.org/10.1093/ofid/ofae140

Vancouver

McLeod SM, Miller AA, Rana K, Altarac D, Moussa SH, Shapiro AB. Clinical Outcomes for Patients With Monomicrobial vs Polymicrobial Acinetobacter baumannii-calcoaceticus Complex Infections Treated With Sulbactam-Durlobactam or Colistin: A Subset Analysis From a Phase 3 Clinical Trial. Open Forum Infectious Diseases. 2024;11(4). doi:10.1093/ofid/ofae140

BibTeX
@article{McLeod2024,
  author = {McLeod, Sarah M and Miller, Alita A and Rana, Khurram and Altarac, David and Moussa, Samir H and Shapiro, Adam B},
  title = {Clinical Outcomes for Patients With Monomicrobial vs Polymicrobial Acinetobacter baumannii-calcoaceticus Complex Infections Treated With Sulbactam-Durlobactam or Colistin: A Subset Analysis From a Phase 3 Clinical Trial},
  journal = {Open Forum Infectious Diseases},
  year = {2024},
  volume = {11},
  number = {4},
  doi = {10.1093/ofid/ofae140}
}
Kostenlos starten →